Heron Therapeutics (HRTX) EBIAT: 2010-2025
Historic EBIAT for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to -$17.5 million.
- Heron Therapeutics' EBIAT fell 260.87% to -$17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.6 million, marking a year-over-year increase of 51.45%. This contributed to the annual value of -$13.6 million for FY2024, which is 87.72% up from last year.
- Heron Therapeutics' EBIAT amounted to -$17.5 million in Q3 2025, which was down 634.78% from -$2.4 million recorded in Q2 2025.
- Over the past 5 years, Heron Therapeutics' EBIAT peaked at $3.7 million during Q4 2024, and registered a low of -$63.9 million during Q1 2022.
- Its 3-year average for EBIAT is -$12.9 million, with a median of -$9.2 million in 2024.
- Within the past 5 years, the most significant YoY rise in Heron Therapeutics' EBIAT was 183.39% (2025), while the steepest drop was 260.87% (2025).
- Over the past 5 years, Heron Therapeutics' EBIAT (Quarterly) stood at -$54.6 million in 2021, then surged by 63.64% to -$19.9 million in 2022, then soared by 46.03% to -$10.7 million in 2023, then soared by 134.16% to $3.7 million in 2024, then plummeted by 260.87% to -$17.5 million in 2025.
- Its EBIAT stands at -$17.5 million for Q3 2025, versus -$2.4 million for Q2 2025 and $2.6 million for Q1 2025.